Filing Details
- Accession Number:
- 0000886163-16-000168
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-05-03 17:34:13
- Reporting Period:
- 2016-05-02
- Filing Date:
- 2016-05-03
- Accepted Time:
- 2016-05-03 17:34:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 886163 | Ligand Pharmaceuticals Inc | LGND | Pharmaceutical Preparations (2834) | 770160744 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1223000 | W John Kozarich | 11119 North Torrey Pines Road, Suite 200 La Jolla CA 92037 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-05-02 | 800 | $121.45 | 43,911 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2016-05-02 | 200 | $122.04 | 43,711 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.98 to $121.90, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.98 to $122.10, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Billionaire Hedge Funds
